42- Pérez Rodríguez ZM, Falcón Lincheta L, Rodríguez Hernández E. Magnetoterapia en pacientes con psoriasis. Rev Cub Med Mil [Internet]. 2011 Dic [citado 2014 Jul 1]; 40(3-4):[aprox. 2 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S013865572011000300010&lng=es.
43- Chiu H, Wang T, Chang C, Tsai T. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol [Internet]. 2012 Aug [cited 2014 Jan 30]; 26(8):[about 9 p.]. Available from: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=601782ab-5d64-4525-b669-0d5284ef4702%40sessionmgr114&vid=1&hid=120.
44- Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) [Internet]. 2014 [cited 2014 jul 1]; 4(1): Available from:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=24452484.
45- Fernándiz Foraster C. Procesos dermatológicos frecuentes. En: Farrera Rozman. Tratado de medicina interna. La Habana: Editorial Ciencias Médicas; 2011. p. 1521-27.
46- Gutierrez Yáñez AS. Psorisis Infantil: Prevalencia y formas clínicas. Nuestra experiencia en un hospital pediátrico público. Rev Argent dermatol [Internet] 2012 [citado 30 Ene 2014]; 93(1): [aprox. 5 p.]. Disponible en: http://www.scielo.org.ar/scielo.php?pid=S1851300X2012000100006&script=sci_arttext.
47- Gourraud P, Le Gall C, Puzenat E, Aubin F, Ortonne J, Paul C. Why Statistics Matter: Limited Inter-Rater Agreement Prevents Using the Psoriasis Area and Severity Index as a Unique Determinant of Therapeutic Decision in Psoriasis. J Invest Dermatol [Internet]. 2012 Sep [cited 2014 Jan 30];132(9):[about 2 p.]. Available from: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=7f5b1b41-c5c0-40b6-93f9-86114893ec46%40sessionmgr111&vid=1&hid=120.
48- Zhu X, Zheng M, Song M, Shen YK, Chan D, Szapary PO, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol [Internet]. 2013 [cited 2014 Jul 1]; 12(2):[about 7 p.]. Available from:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23377389.
49- Noda S, Mizuno K, Adachi M. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. J Dermatol [Internet]. 2012 [cited 2014 Jul 1]; 39(3):[about 1 p.]. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22126280.
50- Villareal Martínez A, Gómez Florez M, Ocampo Candiani J. Agentes biológicos en el tratamiento de la psoriasis. Dermatología CMQ. 2012; 10(3):198-204.
51- Yang HZ, Wang K, Jin HZ, Gao TW, Xiao SX, Xu JH, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chin Med J (Engl) [Internet]. 2012 [cited 2014 Jul 1]; 125(11):[about 8 p.]. Available from:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22884040.